SI2942051T1 - Trdna farmacevtska dozirna oblika, ki vsebuje trdno disperzijo inhibitorja HIV proteaze - Google Patents

Trdna farmacevtska dozirna oblika, ki vsebuje trdno disperzijo inhibitorja HIV proteaze Download PDF

Info

Publication number
SI2942051T1
SI2942051T1 SI200432438T SI200432438T SI2942051T1 SI 2942051 T1 SI2942051 T1 SI 2942051T1 SI 200432438 T SI200432438 T SI 200432438T SI 200432438 T SI200432438 T SI 200432438T SI 2942051 T1 SI2942051 T1 SI 2942051T1
Authority
SI
Slovenia
Prior art keywords
dosage form
pharmaceutical dosage
solid pharmaceutical
use according
pharmaceutically acceptable
Prior art date
Application number
SI200432438T
Other languages
English (en)
Inventor
Jorg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Berndl
Jorg Breitenbach
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2942051(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of SI2942051T1 publication Critical patent/SI2942051T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

  1. Trdna farmacevtska dozirna oblika, ki vsebuje trdno disperzijo inhibitorja HIV proteaze Patentni zahtevki
    1. Trdna farmacevtska dozirna oblika, za uporabo v zdravljenju HIV, kjer dozirna oblika vsebuje trdno disperzijo, ki vsebuje vsak en inhibitor HIV proteaze inhibitor v vsaj enem farmacevtsko sprejemljivem vodotopnem polimeru in vsaj en farmacevtsko sprejemljiv ne-ionski surfaktant, kjer omenjeni inhibitor HIV proteaze vsebuje lopinavir in, kjer omenjeni farmacevtsko sprejemljiv ne-ionski surfaktant vsebuje surfaktant, ki ima vrednost HLB od 4 do 10.
  2. 2. Trdna farmacevtska dozirna oblika za uporabo po zahtevku 1, kjer je omenjena trdna disperzija steklasta raztopina ali trdna raztopina omenjenega vsaj enega inhibitorja HIV proteaze.
  3. 3. Trdna farmacevtska dozirna oblika za uporabo po zahtevku 1 ali zahtevku 2, kjer ima omenjeni surfaktant, ki ima vrednost HLB od 4 do 10, vrednost HLB od 7 do 9.
  4. 4. Trdna farmacevtska dozirna oblika za uporabo po zahtevku 1 ali zahtevku 2, kjer je omenjeni surfaktant, ki ima vrednost HLB od 4 do 10 sorbitan monoester maščobne kisline.
  5. 5. Trdna farmacevtska dozirna oblika za uporabo po zahtevku 4, kjer je omenjeni sorbitan monoester maščobne kisline izbran iz skupine, ki vsebuje sorbitan monolavrat, sorbitan monooleat, sorbitan monopalmitat in sorbitan stearat.
  6. 6. Trdna farmacevtska dozirna oblika za uporabo po kateremkoli predhodnem zahtevku, kjer ima omenjeni farmacevtsko sprejemljiv vodotopni polimer Tg vsaj 50 °C.
  7. 7. Trdna farmacevtska dozirna oblika za uporabo po zahtevku 6, kjer ima omenjeni farmacevtsko sprejemljiv vodotopni polimer Tg od 80 do 180 °C.
  8. 8. Trdna farmacevtska dozirna oblika za uporabo po kateremkoli predhodnem zahtevku, kjer omenjeni farmacevtsko sprejemljiv vodotopni polimer vsebuje homopolimer ali kopolimer N-vinil pirolidona.
  9. 9. Trdna farmacevtska dozirna oblika za uporabo po zahtevku 8, kjer omenjeni farmacevtsko sprejemljiv vodotopni polimer vsebuje kopolimer N-vinilpirolidona in vinil acetat.
  10. 10. Trdna farmacevtska dozirna oblika za uporabo po kateremkoli predhodnem zahtevku, kjer omenjena dozirna oblika vsebuje vsaj en aditiv izbran iz skupine, ki vsebuje regulatorje tečenja, lubrikante, sredstva za povečanje prostornine in razgrajevale.
SI200432438T 2003-08-28 2004-08-23 Trdna farmacevtska dozirna oblika, ki vsebuje trdno disperzijo inhibitorja HIV proteaze SI2942051T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form
EP15169378.5A EP2942051B1 (en) 2003-08-28 2004-08-23 Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion

Publications (1)

Publication Number Publication Date
SI2942051T1 true SI2942051T1 (sl) 2018-06-29

Family

ID=34217089

Family Applications (5)

Application Number Title Priority Date Filing Date
SI200431996T SI2258344T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska odmerna oblika, ki obsega trdno disperzijo ritonavirja in lopinavirja
SI200432438T SI2942051T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska dozirna oblika, ki vsebuje trdno disperzijo inhibitorja HIV proteaze
SI200432412T SI2258346T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska odmerna oblika, ki obsega trdno disperzijo zaviralca proteaze HIV
SI200431719T SI1663183T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska dozirna oblika, ki obsega ritonavir
SI200432367A SI2258345T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska odmerna oblika, ki obsega trdno disperzijo zaviralca proteaze HIV

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200431996T SI2258344T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska odmerna oblika, ki obsega trdno disperzijo ritonavirja in lopinavirja

Family Applications After (3)

Application Number Title Priority Date Filing Date
SI200432412T SI2258346T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska odmerna oblika, ki obsega trdno disperzijo zaviralca proteaze HIV
SI200431719T SI1663183T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska dozirna oblika, ki obsega ritonavir
SI200432367A SI2258345T1 (sl) 2003-08-28 2004-08-23 Trdna farmacevtska odmerna oblika, ki obsega trdno disperzijo zaviralca proteaze HIV

Country Status (31)

Country Link
US (1) US20050048112A1 (sl)
EP (6) EP2258344B1 (sl)
JP (6) JP4815348B2 (sl)
KR (5) KR101132602B1 (sl)
CN (5) CN101919858B (sl)
AT (1) ATE516017T1 (sl)
AU (3) AU2004283087C1 (sl)
CA (2) CA2689639C (sl)
CR (3) CR8256A (sl)
CY (5) CY1111981T1 (sl)
DK (5) DK2942051T3 (sl)
EA (4) EA011924B1 (sl)
EC (1) ECSP066397A (sl)
ES (5) ES2653762T3 (sl)
HK (4) HK1094766A1 (sl)
HR (1) HRP20110555T1 (sl)
HU (3) HUE038792T2 (sl)
IL (3) IL173939A (sl)
ME (2) MEP17608A (sl)
MX (2) MXPA06002346A (sl)
NO (3) NO330282B1 (sl)
NZ (2) NZ545499A (sl)
PL (5) PL2258346T3 (sl)
PT (5) PT2258346T (sl)
RS (2) RS57663B1 (sl)
SG (3) SG179401A1 (sl)
SI (5) SI2258344T1 (sl)
TW (1) TWI342221B (sl)
UA (1) UA85564C2 (sl)
WO (1) WO2005039551A2 (sl)
ZA (3) ZA200801362B (sl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
KR20080091767A (ko) * 2005-12-14 2008-10-14 씨아이피엘에이 엘티디. (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
TW200815033A (en) * 2006-08-10 2008-04-01 Cipla Ltd Antiretroviral solid oral composition
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
SG183059A1 (en) 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
ES2607814T3 (es) * 2008-02-28 2017-04-04 Abbvie Inc. Preparación de tabletas
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
HRP20161154T4 (hr) * 2008-10-07 2023-09-29 Kudos Pharmaceuticals Limited Farmaceutska formulacija 514
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20140066468A1 (en) * 2011-03-07 2014-03-06 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
US20140206717A1 (en) * 2011-08-16 2014-07-24 John Higgins Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2013131646A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
CA2866203A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
EP2900219B1 (en) 2012-09-27 2016-07-06 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
EP2911651B1 (en) 2012-09-27 2016-06-22 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
EP3758683A1 (en) * 2018-03-02 2021-01-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
PT1183026E (pt) 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE60017444T2 (de) 1999-11-12 2006-02-09 Abbott Laboratories, Abbott Park Pharmazeutische formulierungen auf basis fester dispersionen
BR0210520A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
CA2474838C (en) * 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
EP2112925A4 (en) 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS

Also Published As

Publication number Publication date
EA200900292A1 (ru) 2009-06-30
KR20110122771A (ko) 2011-11-10
CN105106104A (zh) 2015-12-02
HUE031153T2 (en) 2017-07-28
PL2258346T3 (pl) 2018-01-31
KR20060121837A (ko) 2006-11-29
EP2258345A2 (en) 2010-12-08
NO20061342L (no) 2006-05-29
PL2942051T3 (pl) 2018-07-31
PT2942051T (pt) 2018-04-23
RS57663B1 (sr) 2018-11-30
CY1118505T1 (el) 2017-07-12
PT2258344E (pt) 2013-02-18
JP2011126898A (ja) 2011-06-30
EP2258344B1 (en) 2012-11-14
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
EA011924B1 (ru) 2009-06-30
EA200600473A1 (ru) 2006-10-27
KR101132602B1 (ko) 2012-04-06
US20050048112A1 (en) 2005-03-03
ES2653762T3 (es) 2018-02-08
ES2367173T3 (es) 2011-10-31
CR8256A (es) 2008-01-11
KR101281994B1 (ko) 2013-07-04
HK1145969A1 (en) 2011-05-13
SI2258346T1 (sl) 2017-12-29
AU2010238573A1 (en) 2010-11-18
AU2007249115A1 (en) 2008-01-10
EP2942051A1 (en) 2015-11-11
CY1113596T1 (el) 2016-06-22
KR20120054666A (ko) 2012-05-30
AU2004283087C1 (en) 2008-04-24
CN102772380B (zh) 2015-08-19
PL2258344T3 (pl) 2013-04-30
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
MEP17608A (en) 2010-06-10
EP2258344A3 (en) 2011-01-19
KR101563222B1 (ko) 2015-10-26
JP2016094433A (ja) 2016-05-26
DK2258345T3 (en) 2017-01-16
HUE038792T2 (hu) 2018-11-28
CY1119651T1 (el) 2018-04-04
IL207260A (en) 2017-10-31
CN1901884A (zh) 2007-01-24
ES2608720T3 (es) 2017-04-12
NO335326B1 (no) 2014-11-10
EP2258345B1 (en) 2016-09-21
CN101919858A (zh) 2010-12-22
HRP20110555T1 (hr) 2011-09-30
SI2258345T1 (sl) 2017-01-31
EP1663183B9 (en) 2012-06-13
ZA200801362B (en) 2009-03-25
JP5903413B2 (ja) 2016-04-13
IL173939A (en) 2017-03-30
CA2536638C (en) 2010-04-06
JP2011236232A (ja) 2011-11-24
PT1663183E (pt) 2011-08-25
HK1217298A1 (zh) 2017-01-06
SI2258344T1 (sl) 2013-03-29
JP2013241460A (ja) 2013-12-05
JP4815348B2 (ja) 2011-11-16
CY1120138T1 (el) 2018-12-12
CR20120662A (es) 2013-03-13
KR101457967B1 (ko) 2014-11-07
NO20131743L (no) 2006-05-29
EA201890737A2 (ru) 2018-08-31
EA201301045A1 (ru) 2014-05-30
DK1663183T3 (da) 2011-08-29
RS20181262A1 (sr) 2019-02-28
EP2258345A3 (en) 2011-01-19
JP2007504142A (ja) 2007-03-01
HK1257502A1 (zh) 2019-10-25
NO330282B1 (no) 2011-03-21
NO334418B1 (no) 2014-03-03
SG145690A1 (en) 2008-09-29
EP2258346A3 (en) 2011-01-19
CN102772380A (zh) 2012-11-14
MXPA06002346A (es) 2006-05-19
ATE516017T1 (de) 2011-07-15
JP5498411B2 (ja) 2014-05-21
SG179401A1 (en) 2012-04-27
PL1663183T3 (pl) 2011-10-31
EA033224B1 (ru) 2019-09-30
HK1094766A1 (en) 2007-04-13
AU2004283087B2 (en) 2007-09-20
ES2399810T3 (es) 2013-04-03
PT2258345T (pt) 2017-01-20
EP1663183A2 (en) 2006-06-07
CN101919858B (zh) 2013-10-30
RS20060140A (en) 2008-09-29
ECSP066397A (es) 2006-08-30
PL2258345T3 (pl) 2017-03-31
CR20120661A (es) 2013-03-13
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
IL173939A0 (en) 2006-07-05
SG10201507902UA (en) 2015-10-29
NZ545499A (en) 2009-11-27
ME00130B (me) 2010-10-10
EA201890737A3 (ru) 2019-01-31
EP2258344A2 (en) 2010-12-08
JP2018035163A (ja) 2018-03-08
NZ579622A (en) 2011-01-28
UA85564C2 (ru) 2009-02-10
CN1901884B (zh) 2012-07-25
DK2258346T3 (da) 2017-11-13
JP5395125B2 (ja) 2014-01-22
NO20100367L (no) 2006-05-29
EP1663183B1 (en) 2011-07-13
HUE035985T2 (hu) 2018-06-28
MX358033B (es) 2018-08-02
CY1111981T1 (el) 2015-11-04
EA020992B1 (ru) 2015-03-31
RS59969B1 (sr) 2020-03-31
WO2005039551A3 (en) 2006-08-03
DK2942051T3 (en) 2018-05-07
ZA200801361B (en) 2011-11-30
CA2536638A1 (en) 2005-05-06
IL254581A0 (en) 2017-11-30
AU2007249115B2 (en) 2010-08-12
AU2010238573B2 (en) 2012-12-13
DK2258344T3 (da) 2013-01-02
AU2004283087A1 (en) 2005-05-06
WO2005039551A2 (en) 2005-05-06
TWI342221B (en) 2011-05-21
KR20140046078A (ko) 2014-04-17
CA2689639A1 (en) 2005-05-06
ZA200601718B (en) 2009-11-25
ES2666390T3 (es) 2018-05-04
EP3354261A1 (en) 2018-08-01
KR20150044031A (ko) 2015-04-23
PT2258346T (pt) 2017-10-24
EP2258346A2 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
SI2942051T1 (sl) Trdna farmacevtska dozirna oblika, ki vsebuje trdno disperzijo inhibitorja HIV proteaze
EP1467970A4 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
WO2004024078A3 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
SI2206500T1 (sl) Trdna farmacevtska dozirna oblika,ki vsebuje lopinavir
HUS1600016I1 (hu) N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok
ATE364385T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
ATE345129T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
NO20014488D0 (no) Amidderivater
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
WO2005086700A3 (en) Hiv integrase inhibitors
DE602004018772D1 (de) Pharmazeutische zusammensetzungen - ph-sensitive blockcopolymere und einen hydrophoben wirkstoff enthaltend
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
SG165162A1 (en) Modified release pharmaceutical formulation
PT1195160E (pt) Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
DE60323743D1 (en) N-(substituierte benzyl)-8-hydroxy-1,6-naphthyridin-7- carbonsäureamide als hiv-integrase-hemmer
DE59910925D1 (de) Mittel mit Copolymerisaten aus N-Vinylcarbonsäureamiden und Monomeren mit hydrophobem Rest, und Verwendung dieser Copolymerisate
AR065720A1 (es) Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ATE404563T1 (de) 8-hydroxy-1- oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen
MX2007005124A (es) Composiciones farmaceuticas espontaneamente dispersables.
CZ20011784A3 (cs) Antibakteriální vodní oční formulace obsahující ofloxacin a pouľití chitosanu
MX2023007710A (es) Formulacion de dispersion solida amorfa.
UA84678C2 (ru) Фармацевтической композиции модифицированного высвобождения соли производного манделовой кислоты и ее применение для лечения сердечнососудистых нарушений